Sign In
Buy PTPI
$0.0058
-0.0001 (-1.69%)
At Close: Jun 23, 2026
Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)
01:30am, Saturday, 21'st Mar 2026
Cuprina Holdings (Cayman) (NASDAQ: CUPR - Get Free Report) and Petros Pharmaceuticals (NASDAQ: PTPI - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We w
Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)
02:20am, Wednesday, 03'rd Dec 2025
Profitability This table compares Statera Biopharma and Petros Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Statera Biopharma N/A
NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the c
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
09:00am, Wednesday, 21'st May 2025
The Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on e
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
09:15am, Tuesday, 20'th May 2025
With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 /
Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petr
Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again (M
Company's AI and Big Data technology positioned to drive strong industry collaboration Company also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmac
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
09:15am, Thursday, 20'th Mar 2025
Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the coun
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
09:20am, Tuesday, 25'th Feb 2025
Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceutic
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
09:25am, Tuesday, 18'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-t
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
09:15am, Tuesday, 07'th Jan 2025
Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharma
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
09:15am, Thursday, 19'th Dec 2024
Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceutic
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
09:00am, Tuesday, 17'th Dec 2024
Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications NEW YORK,
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NAS
